Lytix presents encouraging preclinical data in triple negative breast cancer in collaboration with Weill Cornell Medicine
Presenting poster at SITC
Lytix Biopharma AS announces data showing that the Company’s LTX-315 induces immunotherapeutic and antimetastatic activity in a preclinical breast cancer model that is resistant to immune checkpoint inhibitors. The data will be presented November 13th, 2021, as a poster at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021).
LTX-315 displays anticancer effects against metastatic lesions in the lungs in the triple negative breast cancer model
The data presented at SITC is published in a scientific article in OncoImmunology entitled “LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells”.
In this study, the anticancer effect of LTX-315 in a triple negative breast cancer (TNBC) model that were resistant to checkpoint inhibitor was investigated. Among the different subtypes of breast cancer, TNBC is the most difficult to treat. The TNBC model has several characteristics that make it a suitable experimental animal model for human TNBC.
In the TNBC model, LTX-315 alone displayed anticancer effects against metastasis to the lungs. Earlier preclinical studies have clearly shown the involvement of T cells in the anticancer effect of LTX-315. Here, it was also documented that LTX-315’s anticancer effects involved NK cell activity. The effect of LTX-315 was further improved when combined with radiotherapy and checkpoint inhibitors.
Collaborative research effort
The study was a collaborative research effort between Lytix and the research groups of Drs. Lorenzo Galluzzi and Sandra Demaria at Weill Cornell Medicine, New York. Demaria serves as a paid scientific advisory board member for Lytix Biopharma.
“Intratumoral LTX-315 controlled metastatic dissemination in an immunocompetent model of triple negative breast cancer that is resistant to immune checkpoint inhibitors, at least in part by engaging NK-cell dependent anticancer immunity. Our findings expand the mechanisms whereby LTX-315 controls breast cancer progression,” Galluzzi said.
Scientific evidence of anticancer effects
“These findings provide further scientific evidence for the broad anticancer effect of LTX-315 and the potential to combine LTX-315 with checkpoint inhibitors and conventional therapy,” said Øystein Rekdal (CEO in Lytix Biopharma). He continues: “We are proud to publish these promising data, together with the excellent research teams at Weil Cornell Medicine, led by Sandra Demaria and Lorenzo Galluzzi, in OncoImmunology, a leading journal within the cancer immunology field”.
Sandra Demaria comments: “LTX-315 caused a considerable decrease in the number of macroscopic pulmonary metastases formed by progressing tumors. These study results are consistent with the marked capacity of LTX-315 to elicit tumor specific immunity - through eliciting immunogenic cell death (ICD) in malignant cells documented in previous studies”.
The poster will be available on Lytix' webpage on Saturday November 13th, 2021.